KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Operating Expenses (2020 - 2025)

Esperion Therapeutics' Other Operating Expenses history spans 6 years, with the latest figure at -$185.8 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 824.84% year-over-year to -$185.8 million; the TTM value through Dec 2025 reached -$84.4 million, down 223.05%, while the annual FY2025 figure was -$84.4 million, 223.05% down from the prior year.
  • Other Operating Expenses reached -$185.8 million in Q4 2025 per ESPR's latest filing, down from $41.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $41.3 million in Q3 2025 to a low of -$185.8 million in Q4 2025.
  • Average Other Operating Expenses over 5 years is $3.4 million, with a median of $9.6 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 5654.84% in 2021, then tumbled 824.84% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $5.1 million in 2021, then decreased by 18.03% to $4.2 million in 2022, then skyrocketed by 175.29% to $11.5 million in 2023, then soared by 123.81% to $25.6 million in 2024, then crashed by 824.84% to -$185.8 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Other Operating Expenses are -$185.8 million (Q4 2025), $41.3 million (Q3 2025), and $28.5 million (Q2 2025).